Galderma Secures EU Nod for Restylane Shaype, Expanding Non-Surgical Facial Shaping Market
Event summary
- Galderma received EU approval for Restylane Shaype, a bone-mimicking hyaluronic acid injectable designed for chin augmentation.
- The product is the first of its kind to offer non-surgical structural enhancement in the lower face.
- A pivotal study showed 83% of patients experienced improved structure and definition at three months, with 84% willing to repeat treatment.
- Restylane Shaype is powered by Galderma’s NASHA HD™ technology, offering the firmest HA injectable gel in the market.
The big picture
Galderma’s EU approval for Restylane Shaype marks a strategic milestone in the injectable aesthetics space, addressing a gap in non-surgical lower face augmentation. The product’s bone-mimicking technology positions Galderma to capitalize on growing demand for minimally invasive facial shaping solutions, particularly among patients concerned with chin definition and structural harmony. This approval further solidifies Galderma’s leadership in the dermatology sector, where it continues to innovate with science-based solutions.
What we're watching
- Market Penetration
- How Restylane Shaype will perform against surgical implants in the lower face augmentation market.
- Technological Edge
- Whether Galderma’s NASHA HD™ technology can maintain its lead in firmness and structural support.
- Regulatory Expansion
- The pace at which Restylane Shaype gains approvals in other major markets beyond Europe, Canada, and Brazil.